Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Revance Therapeutics Introduces First Daxxify® for the Treatment of Cervical Dystonia

Revance Therapeutics has introduced a new treatment option named Daxxify® (DaxibotulinumtoxinA-lanm). This is the first approval for the treatment of cervical dystonia in adults.

Daxxify® stands out as the first of its kind long-acting neuromodulator specifically designed to fulfil a significant need in the treatment of cervical dystonia. It offers durable symptom relief even between treatment cycles, allowing for extended periods between treatments.

Daxxify® is an innovative type of medication designed specifically for people with cervical dystonia, a condition where neck muscles involuntarily contract, causing uncomfortable movements and pain. 

Daxxify® having unique neuromodulator is made from peptides, which are small units of proteins. This formulation allows it to have a lasting effect on the symptoms of cervical dystonia.

Daxxify® cosnists of the ability to provide more effective and longer-lasting relief compared to other treatments. This can significantly benefit both patients and doctors.

Daxxify® not only addresses the medical aspect but also considers the economic aspect. By providing lasting relief, it can potentially reduce the overall cost of care for individuals with cervical dystonia.

The U.S. Food and Drug Administration (FDA) has granted approval for the first therapeutic use of Daxxify® (DaxibotulinumtoxinA-lanm) through injection for treating cervical dystonia.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024